Targeted therapies such as tyrosine kinase inhibitor pazopanib as well as anti-CDK4 and anti-MDM2 oncogenes are emerging and may provide future clinical benefits for the treatment of DDLPS.6 This evidence concerns the gene CDK4 and dedifferentiated liposarcoma.